Aquis Stock Exchange does not endorse and is not responsible for this content

  www.incanthera.com

Incanthera plc
AQSE Growth Market



The Company is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and is currently being prepared for licensing to a commercial partner within 12-18 months.

The Company originated from the Institute of Cancer Therapeutics – University of Bradford and, in addition to Sol, has acquired and developed a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

Incanthera plc

Symbol Ccy Code Bid (GBX) Ask Mid Previous Close Volume Last Traded 52Wk Low 52Wk High
INC GBX 15 17 16 16 45,000 05/08/2020 10 16
All data delayed by up to 5 minutes
MIFID II compliant post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 30 minutes.Publication of trades that are large in scale compared to normal market size may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of NEX Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are available here.


Key Information

Market Cap: £9.7M
ISIN: GB00BGL7YW15
Par: 0.0200
Inst Type: ORD
Symbol: INC
MiFID Status: MTF
Tradable securities in issue: 60,859,910
Sector: Pharmaceuticals & Biotechnology

Latest Trades

Date & Time Volume Price
05/08/2020 13:14 45,000 13
20/07/2020 15:33 15,790 15.5
30/06/2020 09:27 5,000 16
30/06/2020 09:23 5,000 16
26/06/2020 15:09 62,142 16
View latest trades

Address

Business Address

76 King Street, Manchester, M2 4NH, United Kingdom

Business Telephone: +44 (0) 161 817 5005

Business Email: laura.brogden@incanthera.com

Registered Address

76 King Street, Manchester, M2 4NH, United Kingdom

Contacts

Corporate Adviser: Cairn Financial Advisers LLP.

Cheyne House, Crown Court, 62 - 63 Cheapside, London, United Kingdom, EC2V 6AX

Phone: +44 (0)20 7148 7900
Email:

Registrar: Neville Registrars Limited

Neville House,Steelpark Road, Halesowen, West Midlands, United Kingdom, B62 8HD

Phone: +44 (0) 121 585 1131
Email: info@nevilleregistrars.co.uk